BACE Inhibitors Clinical Trials & Results, Patent and Other Developments

BACE Inhibitors Pipeline to Witness Huge
R&D Investment in the Coming Years
[email protected]
Beta-Secretase (BACE) Inhibitors Pipeline Analysis
According to a new research report “Beta-Secretase (BACE) Inhibitors Pipeline
Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other
Developments” published by P&S Market Research, BACE inhibitors currently exhibit a
pipeline with estimated 15 drug candidates.
Browse the Report Summary at:
BACE Inhibitors Exhibit an Emerging Pipeline with
10+ Drug Candidates
The study analysed that the Beta Secretase inhibitors pipeline comprised 15
drug candidates, in different stages of development.
Beta-Secretase (BACE) Inhibitors Pipeline Analysis
Insights on pipeline segments
As per the findings of the research, most of the pipeline drug candidates of
BACE inhibitors are being developed to be administered by oral route.
Alzheimer’s disease drug development receives
Fast Track designation
Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and
Eli Lilly and Company, received Fast Track designation by the U.S. Food and
Drug Administration (FDA) in August 2016. The FDA’s Fast Track program
was designed to expedite the development and review new therapies to
treat serious conditions and tackle unmet medical needs.
Beta-Secretase (BACE) Inhibitors Pipeline Analysis
Major companies collaborate for the development
of BACE inhibitors
The research finds that different companies collaborated for the
development of BACE inhibitors. Novartis entered in a global collaboration
with Amgen to commercialize and develop BACE inhibitor program in
September 2015 for Alzheimer's disease.
Some of the key players developing BACE inhibitors are AstraZeneca plc, Eli
Lilly & Company, Johnson & Johnson, and others.
Beta-Secretase (BACE) Inhibitors Pipeline Analysis
Download report sample at:
For information regarding permissions and other queries
Kindly write to:
[email protected]
US/Canada Toll-Free: 1-888-778-7886